The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
about
Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Phase 0 clinical trials in oncology new drug development.The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells.Phase 0 Workshop at the 20th EORTC-NCI-AACR Symposium, Geneva.Microdosing and drug development: past, present and futureOncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patientDesigning phase 0 cancer clinical trials.Principles of dose finding studies in cancer: a comparison of trial designs.Retinoid chemoprevention trials: cyclin D1 in the crosshairs.Embracing model-based designs for dose-finding trials.Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.FGFR-TACC gene fusions in human glioma.Role of Phase 0 trials in drug development.Early human studies of investigational agents: dose or microdose?Brain Tumor Clinical Trials: Perspective 2014.
P2860
Q33408198-DDB44EAC-4A74-4E66-903B-F7FF1311BB65Q33775647-42FFB0A6-E2DD-477B-BEE2-DA5D3BC95D9FQ34941964-AD8CDC46-5034-4CD7-AB90-6541665CC735Q35146271-CA7BEE80-66F8-499E-A36F-FFC8027148ABQ35602195-74028AB5-791D-4D35-8690-4E3910A71B2EQ35940544-A1BB481B-318E-48C1-9EE9-47F71DEF64E9Q36732058-7ADC22EE-310E-4D6A-A235-D4A18033AECBQ36732115-8EA7FE27-79DF-4FE8-8443-D5650BDD7594Q36795347-15537338-3BD8-46A2-93B9-28DBD58C6B4DQ37367075-40B51D15-CE0A-4279-92E2-6EB5F33BDF1EQ38700689-7318AEF5-6609-42F7-9EE7-AD09AED2B856Q38818203-74C9036F-4020-4F19-8724-E8531325DB16Q39010445-2DE5A772-8C8A-4A7F-9AC2-13DEE47AA00BQ39934032-61E122D7-E909-4B2D-977B-10263DF87A41Q41896620-79D3BA96-4AE5-4D74-930D-48E7F34DDBB5Q52151988-3A353636-B90A-4EF6-8D60-FDB515D92C15
P2860
The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The development of phase I can ...... hase 0 cancer clinical trials.
@en
The development of phase I can ...... hase 0 cancer clinical trials.
@nl
type
label
The development of phase I can ...... hase 0 cancer clinical trials.
@en
The development of phase I can ...... hase 0 cancer clinical trials.
@nl
prefLabel
The development of phase I can ...... hase 0 cancer clinical trials.
@en
The development of phase I can ...... hase 0 cancer clinical trials.
@nl
P1476
The development of phase I can ...... hase 0 cancer clinical trials.
@en
P2093
A Hilary Calvert
Ruth Plummer
P304
P356
10.1158/1078-0432.CCR-07-4559
P407
P577
2008-06-01T00:00:00Z